SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, crudeoil24, Apophis, 4on4off
Search This Board: 
Last Post: 7/28/2017 11:02:10 AM - Followers: 112 - Board type: Free - Posts Today: 3

AVEO ONCOLOGY, Inc. (AVEO) 


Company website: 
http://www.aveooncology.com/

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

   

Product pipeline candidates include Tivozanib, Ficlatuzumab, AV-203, AV-353 and AV-380.
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment (Solid Dose) for patients with advanced renal cell carcinoma (RCC)
 

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.

AV-353

AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including cancer, cardiovascular diseases and neurodegenerative conditions. Publications, including Nature Medicine (2009), have implicated the Notch 3 pathway in Pulmonary Arterial Hypertension (PAH). PAH is a rare and life-threatening disorder that affects approximately 250,000 people worldwide and is caused by enlargement of the arterial walls in small arteries between the heart and the lungs, resulting in restricted blood flow.

Current treatments in PAH focus only on controlling symptoms by avoiding vasoconstriction and increasing vasodilation of vessels and do not reverse the underlying cause of the disease. In contrast, with the results of a recently concluded preclinical animal studies supported by AVEO, AV-353 has generated a growing body of preclinical data that supports AV-353’s ability to potentially reverse the disease phenotype, which would represent a potential disease-modifying approach to treatment. AVEO is currently seeking a partner to develop and commercialize AV-353 worldwide in PAH.

For additional information, or to inquire about potential partnering opportunities, please contact Nikhil Mutyal (nmutyal@aveooncology.com).

 
www.aveopharma.com
Shares Outstanding   110,363,000
Insider Ownership 17%
Institutional + Mutual Fund Ownership  51%
20 Full Time Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

 
AVEO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO News: Statement of Changes in Beneficial Ownership (4) 07/05/2017 04:33:43 PM
AVEO News: Statement of Changes in Beneficial Ownership (4) 06/28/2017 05:12:45 PM
AVEO News: Statement of Changes in Beneficial Ownership (4) 06/28/2017 05:12:45 PM
AVEO News: Current Report Filing (8-k) 06/27/2017 04:34:52 PM
AVEO News: AVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock Offerings 06/27/2017 09:06:00 AM
PostSubject
#2586  Sticky Note AVEO Oncology Announces $14M in Aggregate Gross Proceeds ProfitScout 06/27/17 11:08:53 AM
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#2893   Thanks, n3m3sis. I posted over on Avx* powerwalker 07/28/17 11:02:10 AM
#2892   Great read. Thanks for that! twistedfreak 07/28/17 07:51:45 AM
#2891   Illegal Naked Short Selling Appears to Lie at n3m3sis 07/28/17 07:05:18 AM
#2890   patience! harry crumb 07/27/17 05:15:31 PM
#2889   yeah, possible. we own exel at 4$ an harry crumb 07/27/17 05:09:45 PM
#2888   My thinking exactly! n3m3sis 07/27/17 11:26:50 AM
#2887   maybe, maybe not. If the stars are in twistedfreak 07/27/17 10:56:36 AM
#2886   all that short interest this month and yet twistedfreak 07/27/17 10:51:31 AM
#2885   also, expect a buyout frenzy to begin harry crumb 07/27/17 09:46:19 AM
#2884   institutional ownership is now at over 50% of harry crumb 07/27/17 09:45:40 AM
#2883   8 million shares is about half a days Apophis 07/27/17 09:40:20 AM
#2882   AVEO Pharmaceuticals, Inc. Short Interest Up 98.9% in July! n3m3sis 07/27/17 09:36:19 AM
#2881   They already have batches of product produced for Apophis 07/27/17 09:21:54 AM
#2880   Hopefully a big news release within a week. Apophis 07/27/17 08:17:30 AM
#2879   I know some get kicked out the last Apophis 07/26/17 01:23:28 PM
#2878   Dear Mr XXXXXX, twistedfreak 07/25/17 03:49:42 PM
#2877   It would be nice to start being slow Apophis 07/24/17 05:36:21 PM
#2876   One more piece of news even if it Apophis 07/24/17 11:57:29 AM
#2875   like i mentioned, this is a fuse burning harry crumb 07/24/17 11:10:41 AM
#2874   Hopefully the short selling ends this week Apophis 07/24/17 08:30:52 AM
#2873   agree, like i said 1 good news release harry crumb 07/23/17 10:44:58 PM
#2872   Short interest has dropped under 2% , this Apophis 07/23/17 05:32:22 PM
#2871   its going up, each day is closer an harry crumb 07/21/17 10:39:48 PM
#2870   Beware!!! Of chart posters bearing gifts! n3m3sis 07/21/17 07:14:59 PM
#2869   AVEO buy 2.52 stocktrademan 07/20/17 08:51:46 PM
#2868   indeed harry crumb 07/20/17 12:46:11 PM
#2867   agree an yes you are correct. 5$ is harry crumb 07/20/17 09:31:36 AM
#2866   That new report on institutional holders just hit Apophis 07/20/17 08:28:55 AM
#2865   AVEO Pharmaceuticals Inc, Inst Holders, 2Q 2017 (AVEO) Apophis 07/20/17 08:27:22 AM
#2864   It would be nice to see it close Apophis 07/20/17 08:20:46 AM
#2863   Agree. That's their problem, not mine. Glad I twistedfreak 07/20/17 08:17:56 AM
#2862   Many will be sorry they took a profit Apophis 07/20/17 08:14:07 AM
#2861   Agree Apop. IMO, AVEO (or EUSA)is now ramping twistedfreak 07/20/17 06:49:41 AM
#2860   Five bucks here once the approval is announced Apophis 07/19/17 10:03:39 PM
#2859   Another big insider buy would do right now Apophis 07/19/17 09:53:35 PM
#2858   * * $AVEO Video Chart 07-19-17 * * ClayTrader 07/19/17 04:55:07 PM
#2857   1 just 1 news release an i doubt harry crumb 07/19/17 11:42:45 AM
#2856   added last few days from 2.37 thru 2.65, harry crumb 07/19/17 11:40:20 AM
#2855   I guess with summer trading this thing can Franyeld 07/19/17 03:09:13 AM
#2854   That wouldn't hurt my feelings at all 4on4off 07/18/17 08:49:22 PM
#2853   buyout possible! harry crumb 07/18/17 08:27:51 PM
#2852   take a hike jacko! harry crumb 07/18/17 06:41:36 PM
#2851   * * $AVEO Video Chart 07-18-17 * * ClayTrader 07/18/17 05:17:49 PM
#2850   FALSE STATEMENTS.... AKsquared 07/18/17 05:08:39 PM
#2849   talked to a broker, he said the shorts harry crumb 07/18/17 04:50:13 PM
#2848   $AVEO YES! 4.50 EASY ON APPROVAL AND FAST! 4on4off 07/18/17 01:53:30 PM
#2847   $AVEO absolutely shorty will be burned when approval 4on4off 07/18/17 01:52:23 PM
#2846   Next release of approval will put it over $4.50 Apophis 07/18/17 11:40:34 AM
#2845   anyone short on this is absolutely crazy to harry crumb 07/18/17 11:34:43 AM
#2844   Total bullshit. Nice try. welcome to the board 4on4off 07/18/17 10:09:37 AM
PostSubject